| TILDRAKIZUMAB |
Ilumya® |
SUN PHARMA ANZ PTY LTD |
Severe chronic plaque psoriasis |
Mar 2026 |
Recommended |
| USTEKINUMAB |
Ardelya® |
SANDOZ PTY LTD |
Severe chronic plaque psoriasis Severe psoriatic arthritis |
Mar 2026 |
Recommended |
| TAFAMIDIS |
Vyndamax® |
PFIZER AUSTRALIA PTY LTD |
Transthyretin amyloid cardiomyopathy (ATTR-CM) |
Mar 2026 |
Not Recommended |
| CANAKINUMAB |
Ilaris® |
NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED |
Colchicine-resistant or intolerant Familial Mediterranean Fever (crFMF) |
Mar 2026 |
Recommended |
| AVACINCAPTAD PEGOL |
Izervay® |
ASTELLAS PHARMA AUSTRALIA PTY LTD |
Geographic atrophy (GA) secondary to age-related macular degeneration (AMD) |
Mar 2026 |
Recommended |
| DUPILUMAB |
Dupixent® |
SANOFI-AVENTIS AUSTRALIA PTY LTD |
Chronic obstructive pulmonary disease (COPD) |
Mar 2026 |
Recommended |
| LANREOTIDE |
Lacreo |
SUN PHARMA ANZ PTY LTD |
Acromegaly Functional carcinoid tumour Non-functional gastroenteropancreatic neuroendocrine
tumour (GEP-NET) |
Mar 2026 |
Recommended |
| GLYCOMACROPEPTIDE FORMULA WITH DOCOSAHEXAENOIC ACID AND LOW PHENYLALANINE |
PKU GMPro® Delight |
NUTRICIA AUSTRALIA PTY LIMITED |
Phenylketonuria (PKU) |
Mar 2026 |
Recommended |
| EFGARTIGIMOD ALFA |
Vyvgart® |
ARGENX AUSTRALIA PTY. LTD. |
Chronic inflammatory demyelinating polyneuropathy (CIDP) |
Mar 2026 |
Not Recommended |
| DURVALUMAB |
Imfinzi® |
ASTRAZENECA PTY LTD |
Gastric cancer (GC) or gastro-oesophageal junction cancer (GOJC) |
Mar 2026 |
Recommended |
| ADALIMUMAB |
Yuflyma® |
CELLTRION HEALTHCARE AUSTRALIA PTY LTD |
Moderate to severe ulcerative colitis Severe juvenile idiopathic arthritis Severe
chronic plaque psoriasis Severe Crohn disease Vision-threatening non-infectious uveitis |
Mar 2026 |
Recommended |
| ASCIMINIB |
Scemblix® |
NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED |
Chronic myeloid leukaemia (CML) |
Mar 2026 |
Recommended |
| EFGARTIGIMOD ALFA |
Vyvgart® |
ARGENX AUSTRALIA PTY. LTD. |
Generalised myasthenia gravis (gMG) |
Mar 2026 |
Recommended |
| OBINUTUZUMAB |
Gazyva® |
ROCHE PRODUCTS PTY LTD |
Lupus nephritis |
Mar 2026 |
Recommended |
| UPADACITINIB |
Rinvoq® |
ABBVIE PTY LTD |
Fistulising Crohn’s disease (FCD) |
Mar 2026 |
Recommended |
| PEGCETACOPLAN |
Empaveli® |
SWEDISH ORPHAN BIOVITRUM PTY LTD |
Complement 3 glomerulopathy (C3G) or primary immune complex membranoproliferative
glomerulonephritis (IC-MPGN) |
Mar 2026 |
Not Recommended |
| RISPERIDONE |
Uzedy® |
TEVA PHARMA AUSTRALIA PTY LTD |
Schizophrenia |
Mar 2026 |
Recommended |
| TECLISTAMAB |
Tecvayli® |
JANSSEN-CILAG PTY LTD |
Relapsed or refractory multiple myeloma (RRMM) |
Mar 2026 |
Recommended |
| SELPERCATINIB |
Retevmo® |
ELI LILLY AUSTRALIA PTY LTD |
Medullary thyroid cancer (MTC) |
Mar 2026 |
Recommended |
| NEMOLIZUMAB |
Nemluvio® |
GALDERMA AUSTRALIA PTY LTD |
Atopic dermatitis |
Mar 2026 |
Recommended |
| INOTUZUMAB OZOGAMICIN |
Besponsa® |
PFIZER AUSTRALIA PTY LTD |
Acute lymphoblastic leukaemia (ALL) |
Mar 2026 |
Advice Provided |
| ODEVIXIBAT |
Bylvay® |
IPSEN PTY LTD |
Alagille syndrome (ALGS) |
Mar 2026 |
Not Recommended |
| MEPOLIZUMAB |
Nucala® |
GLAXOSMITHKLINE AUSTRALIA PTY LTD |
Chronic obstructive pulmonary disease (COPD) |
Mar 2026 |
Recommended |
| ENZALUTAMIDE |
Xtandi® |
ASTELLAS PHARMA AUSTRALIA PTY LTD |
Non-metastatic hormone sensitive prostate cancer (nmHSPC) |
Mar 2026 |
Recommended |
| ROMIDEPSIN |
Romidepsin-Reach |
REACH PHARMACEUTICALS PTY LTD |
Relapsed or refractory peripheral T-cell lymphoma |
Mar 2026 |
Recommended |
| AMIVANTAMAB |
Rybrevant® |
JANSSEN-CILAG PTY LTD |
Non-small cell lung cancer (NSCLC) |
Mar 2026 |
Recommended |
| ADALIMUMAB |
Amgevita® |
AMGEN AUSTRALIA PTY LIMITED |
Crohn disease Ulcerative colitis Active juvenile idiopathic arthritis Complex refractory
fistulising Crohn disease Active rheumatoid arthritis Psoriatic arthritis Ankylosing
spondylitis Chronic plaque psoriasis Hidradenitis suppurativa |
Mar 2026 |
Recommended |
| RUXOLITINIB |
Jakavi® |
NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED |
Myelofibrosis Graft versus host disease Polycythemia vera |
Mar 2026 |
Recommended |
| BIRCH TRITERPENES |
Filsuvez® |
CHIESI AUSTRALIA PTY LTD |
Dystrophic or junctional epidermolysis bullosa (EB) |
Mar 2026 |
Not Applicable |
| PEGVALIASE |
Palynziq® |
BIOMARIN PHARMACEUTICAL AUSTRALIA PTY LTD |
Phenylketonuria (PKU) |
Mar 2026 |
Deferred |
| TARLATAMAB |
Imdelltra® |
AMGEN AUSTRALIA PTY LIMITED |
Extensive-stage small cell lung cancer (ES-SCLC) |
Mar 2026 |
Not Recommended |
| TRASTUZUMAB DERUXTECAN |
Enhertu® |
ASTRAZENECA PTY LTD |
Breast cancer |
Mar 2026 |
Not Recommended |
| CANNABIDIOL |
Epidyolex® |
JAZZ PHARMACEUTICALS ANZ PTY LTD |
Severe myoclonic epilepsy in infancy (Dravet syndrome) |
Mar 2026 |
Recommended |
| ENOXAPARIN |
Clexane® Safety-Lock Clexane® Forte Safety-Lock |
SANOFI-AVENTIS AUSTRALIA PTY LTD |
Prevention and treatment of thrombo-embolic disorders Haemodialysis |
Mar 2026 |
Not Applicable |
| RILUZOLE |
Teglutik® |
ASTERI PHARMA PTY LTD |
Amyotrophic lateral sclerosis |
Mar 2026 |
Advice Provided |
| INCOBOTULINUMTOXINA |
Xeomin® |
MERZ AUSTRALIA PTY LTD |
Moderate to severe spasticity of the lower limb in adults following an acute event |
Mar 2026 |
Recommended |
| LONCASTUXIMAB TESIRINE |
Zynlonta® |
SWEDISH ORPHAN BIOVITRUM PTY LTD |
Diffuse large B-cell lymphoma (DLBCL) |
Mar 2026 |
Not Recommended |
| OMALIZUMAB |
Omlyclo® |
CELLTRION HEALTHCARE AUSTRALIA PTY LTD |
Uncontrolled severe asthma Uncontrolled severe allergic asthma Severe chronic spontaneous
urticaria |
Mar 2026 |
Recommended |
| NIVOLUMAB |
Opdivo® |
BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD |
Malignant melanoma Non-Small Cell Lung Cancer (NSCLC) Renal Cell Carcinoma (RCC) Squamous
Cell Carcinoma of the Head and Neck (SCCHN) Urothelial Carcinoma (UC) Oesophageal
/ Gastro-oesophageal cancers(OC/GC) |
Mar 2026 |
Recommended |
| CICLOSPORIN |
Vevye® |
AFT PHARMACEUTICALS (AU) PTY LTD |
Dry eye disease with keratitis |
Mar 2026 |
Recommended |
| EDARAVONE |
Radicava® |
TEVA PHARMA AUSTRALIA PTY LTD |
Amyotrophic lateral sclerosis (ALS) |
Mar 2026 |
Recommended |
| ASCIMINIB |
Scemblix® |
NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED |
Chronic myeloid leukaemia (CML) |
Mar 2026 |
Not Applicable |
| ADRENALINE (EPINEPHRINE) |
Neffy® |
SEQIRUS (AUSTRALIA) PTY LTD |
Acute allergic reaction with anaphylaxis |
Mar 2026 |
Recommended |
| BUROSUMAB |
Crysvita ® |
KYOWA KIRIN AUSTRALIA PTY LTD |
Tumour induced osteomalacia (TIO) |
Mar 2026 |
Recommended |
| VORASIDENIB |
Voranigo® |
SERVIER LABORATORIES (AUST.) PTY. LTD. |
Astrocytoma or oligodendroglioma |
Mar 2026 |
Recommended |
| TOFERSEN |
Qalsody® |
BIOGEN AUSTRALIA PTY LTD |
Amyotrophic lateral sclerosis (ALS) |
Mar 2026 |
Recommended |
| TIRZEPATIDE |
Mounjaro® Mounjaro® KwikPen® |
ELI LILLY AUSTRALIA PTY LTD |
Type 2 diabetes mellitus |
Mar 2026 |
Recommended |
| TACROLIMUS |
aZematop® |
ARROTEX PHARMACEUTICALS PTY LTD |
Atopic dermatitis |
Mar 2026 |
Recommended |
| RETIFANLIMAB |
Zynyz® |
SPECIALISED THERAPEUTICS ALIM PTY LTD |
Merkel cell carcinoma (MCC) |
Mar 2026 |
Recommended |
| RETIFANLIMAB |
Zynyz® |
SPECIALISED THERAPEUTICS ALIM PTY LTD |
Squamous cell anal carcinoma (SCAC) |
Mar 2026 |
Recommended |
| TAFASITAMAB |
Minjuvi® |
SPECIALISED THERAPEUTICS ALIM PTY LTD |
Relapsed and/or refractory follicular lymphoma (FL) |
Mar 2026 |
Recommended |